Mitochondrial Dysfunction in Parkinson s Disease: New Mechanistic Insights and
Therapeutic Perspectives
#MMPMID29616350
Park JS
; Davis RL
; Sue CM
Curr Neurol Neurosci Rep
2018[Apr]; 18
(5
): 21
PMID29616350
show ga
PURPOSE OF REVIEW: Parkinson's disease (PD) is a complex neurodegenerative
disorder, the aetiology of which is still largely unknown. Overwhelming evidence
indicates that mitochondrial dysfunction is a central factor in PD
pathophysiology. Here we review recent developments around mitochondrial
dysfunction in familial and sporadic PD, with a brief overview of emerging
therapies targeting mitochondrial dysfunction. RECENT FINDINGS: Increasing
evidence supports the critical role for mitochondrial dysfunction in the
development of sporadic PD, while the involvement of familial PD-related genes in
the regulation of mitochondrial biology has been expanded by the discovery of new
mitochondria-associated disease loci and the identification of their novel
functions. Recent research has expanded knowledge on the mechanistic details
underlying mitochondrial dysfunction in PD, with the discovery of new therapeutic
targets providing invaluable insights into the essential role of mitochondria in
PD pathogenesis and unique opportunities for drug development.
|Animals
[MESH]
|Antiparkinson Agents/pharmacology/*therapeutic use
[MESH]
free
free
free
